Transaction Information
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or "Calidi") announced the closing of its public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants, a Tranche Series B Unit Warrants, and a Tranche Series C Unit Warrants, for aggregate gross proceeds of approximately $6.1 million, before deducting placement agent fees and other offering expenses.
Ladenburg Thalmann & Co. Inc. acted as the sole placement agent of the offering.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. For more information, please visit www.calidibio.com.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.